AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC

Stock Information for AVEO Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.